Astral Q1 FY27: consolidated PAT +52% YoY on margin expansion, below own preview range
PAT +51.8% YoY · revenue +15.9% · margins expanding · miss vs street
₹1,578 Cr
+15.9% YoY
₹120.2 Cr
+51.8% YoY
7.56%
+1.8pp YoY
₹4.47
Astral's consolidated revenue came in at ₹1,578.0 Cr, up 15.9% YoY (matching management's own release exactly), with PAT of ₹120.2 Cr, up 51.8% YoY. EBITDA of ₹244.0 Cr was up 25.8% YoY — again matching management's stated figure — with EBITDA margin expanding to ~15.5% from ~14.3% a year ago and net profit margin to 7.6% from 5.8%. Sequentially the quarter looks weaker, with revenue down 24.4% and PAT down 43.6% QoQ off Q4 FY26's seasonal peak (Q4 is typically the strongest quarter for plumbing/pipes ahead of the monsoon) — that QoQ drop is a seasonality artifact, not a demand signal, and the YoY read is the one that matters here.
Q1 FY-2027 vs prior quarters
Plumbing, still roughly two-thirds of consolidated revenue, grew 10.1% YoY to ₹1,050.5 Cr with segment margin expanding sharply to 13.5% from 10.4% — the main profit driver this quarter. Paints & Adhesives revenue jumped 29.5% YoY to ₹527.5 Cr, but that growth is partly inorganic: Astral Chemie closed the acquisition of a 60% stake in Differentiated & Sustainable Solutions LLP (DSS, specialty chemicals) on June 11, 2026 for an upfront ₹39.1 Cr, and DSS is consolidated for the first time this quarter — the filing itself flags the segment as not comparable to previous periods. Segment margin in Paints & Adhesives actually compressed to 3.7% from 4.8% YoY, so this quarter's profit growth is a plumbing story, not a paints one.
The stock went into the print at ₹1,464, up 7.8% over the past month of trading.
What the summary numbers don't show
Standalone PAT ₹135.8 Cr, +40.6% YoY on standalone revenue ₹1,367.8 Cr, +13.3% YoY — standalone growth trails consolidated
Management expressed strong confidence for FY27, forecasting 8-10% volume growth in the piping industry, with value growth expected to be higher due to polymer price increases. The company anticipates 15-20% revenue growth for its adhesive and paint businesses in India, with UK operations also expecting double-digit gr
— This quarter: met
Actual results trail our own pre-result preview range (revenue ₹1,650-1,750 Cr, PAT ₹130-150 Cr): both the ₹1,578 Cr revenue and ₹120 Cr PAT came in below the low end. Public Q1-specific consensus was sparse per that preview, so this range is the best available yardstick, and the shortfall looks like a seasonality/timing gap rather than a demand problem given the strong YoY growth. Against management's own FY27 guidance from the May 2026 concall (8-10% piping volume growth, 15-20% adhesive/paint revenue growth, improving margins across segments, CPVC resin plant by Q4 FY27), the quarter is broadly on track — plumbing's 10.1% YoY growth sits near guidance and EBITDA margin expanded — but the Paints & Adhesives margin move is the wrong direction against management's explicit aim of improved segment margins and a positive-EBITDA paint business, even though that segment stayed EBITDA-positive.
W1
Paints & Adhesives segment margin (3.7% this quarter, down from 4.8% YoY) against management's FY27 aim of 'positive EBITDA in the paint segment' and 'improved margins across segments'
W2
CPVC resin plant commissioning targeted by Q4 FY27 per management guidance — watch for the margin lift it's expected to bring
W3
Whether plumbing volume/value growth holds near the 8-10% FY27 guidance band as the DSS-driven Paints & Adhesives consolidation continues
Plumbing momentum into Q1—can Astral sustain the 25% growth trajectory?
Astral reports Q1 FY-27 results on August 12. After Q4's 24% revenue leap driven by plumbing volume surge, the Street watches whether the pipes business momentum carries into the seasonally lighter first quarter, and whether the withdrawn demerger signals renewed focus on the core.
What to expect
~₹1,650–1,750 Cr
Run-rate tracking FY26 exit of ₹2,089 Cr (seasonally lighter Q1 vs Q4)
~₹1,200–1,280 Cr
On-plan if volume growth sustains 20%+ YoY, pricing stable
~19–20%
Q4 plumbing was 19.1% (₹292 Cr / ₹1,534 Cr); watch for cost normalization
~₹130–150 Cr
Tracking 5-6% of revenue; Q4 was ₹213 Cr (end-of-year seasonal)
A strong Q1 reads: revenue ₹1,750 Cr+, plumbing volumes 22%+ YoY, segment margins firm at 19–20%. Signals the momentum from Q4 is structural, not one-time. A weak Q1 reads: revenue <₹1,650 Cr, plumbing growth slips below 15%, margin compression below 18% (input cost pressure or pricing erosion). That would flag either cooling end-user demand or post-scheme reorganization friction.
Is Astral on track?
Yes, broadly. Q4 FY26 revenue of ₹2,089 Cr (+24.2% YoY) and plumbing at ₹1,534 Cr (+25.1%) were the strongest results in at least four quarters. The plumbing volume growth (24.2%) matching revenue growth—not pricing—suggests organic, sustainable momentum in a core end-market (real-estate, water utilities, construction). Full-year FY26 revenue was ₹6,569 Cr (+13%), so Q1 FY27 run-rate of ₹1,650–1,750 Cr represents continuity, not deceleration. PAT growth lags revenue (FY26 +3% vs revenue +13%), a margin headwind to monitor; Q4 PAT was +20%, so the quarterly profile is choppy.
What the Street says
Since last quarter—the scan
1 · Composite Scheme withdrawn (Jul 29)
Board abandoned the demerger of chemicals (₹1,266 Cr, ~21% of FY26 revenue) after independent consultant advised against it. Reason: chemicals lacks scale for standalone growth. Read: Management repriorritising plumbing as the lead business. No deal risk, no shareholder vote friction. Likely neutral to mildly positive—removes uncertainty, frees up management bandwidth.
2 · DSS acquisition (Jun 11)
Astral Chemie (chemicals subsidiary) acquired 60% of Differentiated and Sustainable Solutions LLP for ₹39.11 Cr. Niche play in sustainable materials. Read: Inorganic bolt-on within chemicals; immaterial to Q1 P&L.
3 · Dividend: ₹2.50 / share for FY26 (record date Aug 14)
Final dividend of ₹2.50 on a ₹1 par (250% payout). Signal of confidence and strong cash generation post-Q4 surge. Routine.
4 · AGM: August 24
30th Annual General Meeting via VC. Shareholder approval on results, dividend, director re-election (MD Sandeep Engineer re-appointed for 2027–2032 term). No regulatory noise.
5 · Insider trading window: closed (Jun 25)
Standard closure before results; re-opens post-announcement. No pledges or bulk deals flagged in recent data.
Key macro & ownership shifts
FII selling (−570 bps) has been persistent and is the main drag on the stock (−18% from ATH of ₹1,769). Domestic institutions have stepped in. No major pledges or block deals. The price weakness despite 24% revenue growth and 22 buy ratings suggests valuation reset (earnings multiple compression) is pricing in either cyclical demand weakness or a re-rating on returns. Watch the Q1 result for management colour on order book and pipeline—if they signal sustained 20%+ plumbing growth, the FII selling may be overdone.
Result day—three to watch
1 · Plumbing volume growth sustainability
Q4 was 24.2% (matching revenue). If Q1 is 15–18%, the market reads it as cyclical slowdown (seasonality, end-user caution). If it's 20%+, momentum is structural. Management should give colour on order pipeline and any pricing headwinds.
2 · Segment margin story
Plumbing margins were 19.1% in Q4. Input costs (PVC resin, logistics) are key. If margins expand or hold, it's a vote of confidence. If they compress below 18%, watch for pricing power erosion or raw-material spike.
3 · Chemicals & adhesives trajectory post-demerger withdrawal
Adhesives profit fell 45% in Q4 (₹41.4 Cr → ₹22.8 Cr). Since the demerger is off, management must articulate the standalone or acquisition strategy for chemicals to arrest the bleed. No new guidance = red flag.
Astral's Q1 FY27 preview hangs on a single thread: can the plumbing business sustain the 25% volume momentum into a seasonally lighter quarter? Q4 delivered 24% revenue growth and crushed volume forecasts; the Street's 20% net-income CAGR assumes that sticks. But FII selling (570 bps in nine months) and a 18% pullback from ATH signal the market is pricing either a reversion or a higher discount rate for industrials. The withdrawn demerger is neutral to positive—it clears uncertainty and refocuses the board on plumbing dominance. Expect the stock to re-rate on the Q1 result only if management backs a 20%+ plumbing growth guide and signals margin stability. A 15–18% growth miss or margin compression will invite fresh selling.
Focus the Q1 print: plumbing volume %, segment margin, and management's FY27 full-year guidance on the core business.
Strong YoY growth masks a seasonal cliff — and the street is already skeptical
Revenue and profit surged 15.9% and 51.8% year-over-year, beating prior guidance. But a 24.4% sequential revenue drop on the back of an abnormally strong Q4 raises the real question: how much of this growth is structural, and how much is the calendar?
Astral delivered Q1 revenue of ₹1,578 Cr and net profit of ₹120.2 Cr, with year-over-year growth of 15.9% and 51.8% respectively. These figures align with management's prior guidance of 15–20% growth in adhesives and paints, and 8–10% volume growth in piping. On the surface, this is a clear beat. But the quarter masks a sharp sequential deterioration: revenue fell 24.4% and PAT fell 43.6% compared to the prior quarter, implying Q4 FY26 was abnormally strong or Q1 is seasonally weak. The call transcript is not available to clarify this tension, leaving the market to infer what happened.
Validation: what holds up from the call
Revenue growth aligned with piping industry guidance. Q1 delivered ₹1,578 Cr, up 15.9% YoY, placing it squarely in the 15–20% range management flagged for adhesives and paints.
Strong profit growth and operational leverage. PAT of ₹120.2 Cr up 51.8% YoY confirms that scale gains are flowing to the bottom line, despite flat margins (OPM 14.7%, NPM 7.6%).
Sequential momentum contradicted. Revenue down 24.4% quarter-on-quarter, PAT down 43.6%. This is not a sign of building momentum into H2 — it is seasonal or cyclical weakness that management must explain.
₹1,578 Cr
YoY +15.9% | QoQ −24.4%
₹120.2 Cr
YoY +51.8% | QoQ −43.6%
14.7% / 7.6%
Flat YoY; margin pressure evident
The tension: seasonal or structural?
A 24.4% sequential revenue decline is steep by any measure. Either Q4 FY26 was an outlier (unusual strength), or Q1 is a trough quarter for the piping and adhesive businesses. Without the call transcript, we cannot hear management's explanation or assess their confidence that this is temporary. What we do know: the company guided for 8–10% volume growth in piping and strong growth in adhesives and paints. Q1's YoY performance meets that, but the quarter-on-quarter cliff signals that the path to H2 results is not a straight line upward. CPVC backward integration — a multi-quarter ramp — is baked into guidance, but the sequential breakdown raises questions about execution pace and demand sustainability.
How the market is reading it
The stock surged 8.74% on day 1 following the result announcement, a vote of confidence in the YoY numbers and the guidance trajectory. By day 3, the move had moderated to +5.08%, suggesting the initial euphoria did not hold entirely — a signal that investors are absorbing the QoQ weakness as cautionary rather than ignorable. More telling: FII ownership has trended sharply downward over the past year, falling from 20.14% in Q1 FY26 to 13.89% in Q1 FY27, a decline of 625 basis points. Even as the company delivered, foreign institutions have been trimming exposure. At ₹1,520, the stock trades 14.06% below its all-time high but 15.89% above its 52-week low — it is not cheap, and it is not yet recovered. The RSI of 56.5 is neutral, the stock trades above its 20-, 50-, and 200-day simple moving averages, but the FII sell-off is the market's quiet verdict: there is skepticism beneath the headline growth numbers.
Margin and cost pressure
Operating margin of 14.7% and net margin of 7.6% are flat year-over-year despite revenue growth of 15.9%. This suggests that input costs (polymer prices, raw materials) are rising in line with revenue, offering no margin expansion. Management had flagged that polymer price increases would support value growth (higher prices, not just volume), but the flat margin outcome indicates that pricing gains are being offset by input inflation or competitive pressure. This is a structural constraint worth monitoring — if volumes grow but margins compress, the profit leverage story weakens.
What changed this quarter
No new product launches, licensing updates, or strategic shifts are evident from the available data. The quarter appears to be a continuation of the prior strategy: CPVC backward integration ongoing, adhesives and paints growing in mid-teens, UK operations expected to deliver double-digit growth in H2. The risk is that without call commentary, we are flying blind on management's confidence level, updated timelines, and any headwinds that may have materialized.
YoY growth of 15.9% / 51.8% meets or beats prior guidance
CPVC backward integration underway; adhesives/paints in mid-teens growth
Diversified across piping, adhesives, paints, and UK — reduces single-segment risk
QoQ revenue down 24.4%, PAT down 43.6% — unexplained without call
Margins flat (OPM 14.7%, NPM 7.6%) despite 15.9% revenue growth — input cost pressure
FII ownership collapsed 625 bps over 12 months — institutions trimming despite positive results
Seasonality / cyclical demand
HighQ1 QoQ revenue decline of 24.4% signals pronounced seasonal weakness or a Q4 anomaly. If sequential weakness persists into Q2, the full-year guidance is at risk. Without call clarity, the seasonal pattern is opaque.
Input cost / margin pressure
MediumOPM and NPM flat YoY despite 15.9% revenue growth. Polymer price increases (which management flagged as positive) are not translating to margin expansion. If input costs remain elevated, profit leverage will continue to stall.
Call transcript unavailable
HighThe earnings call is the primary venue for management guidance, Q&A, and forward commentary. Its absence limits our ability to assess management confidence, explain the QoQ dip, or validate H2 outlook. Valuations depend on forward visibility.
FII exit during positive results
MediumFII ownership fell 625 bps over 12 months, including a 61 bp drop this quarter despite strong YoY results. This suggests institutional skepticism about sustainability or valuation. It is a yellow flag on positioning.
1 · Q2 sequential revenue recovery
The critical question is whether Q2 revenue rebounds materially from the Q1 level of ₹1,578 Cr. A sequential recovery would confirm that Q1 was a seasonal trough. A flat or further declining reading would signal deeper cyclical or competitive headwinds and warrant a guidance cut.
2 · Margin trajectory and input cost pass-through
OPM and NPM have been flat YoY for two quarters. Watch for evidence of margin expansion in H2 — either from pricing power (value-led growth in adhesives/paints), operational scale, or easing of input costs. Persistent flat margins despite revenue growth would indicate pricing power is absent.
3 · CPVC backward integration execution and H2 UK double-digit growth realization
Management flagged these as key drivers for FY27. Monitor quarterly updates on capex spend, backward integration production ramp, and UK segment revenue to confirm these initiatives are on track. Any delays here would require guidance to be cut.
Astral delivered a steady Q1 within guidance, but the market's tempered reaction — the day-1 pop fading to +5.08% by day 3, and the FII sell-off — reflects the real unease: strong YoY growth in a seasonally weak quarter is not the same as building momentum. Without the call transcript, we are left to infer whether this QoQ dip is the calendar or a sign of demand softness. The number to track from here is sequential revenue. If Q2 recovers, this is a buy-on-dip story for patient holders. If it stalls, the guidance and valuation are both at risk.
Rating: Hold until Q2 clarifies the sequential trend.